Baker Brothers Advisors

Julian and Felix Baker are the sole investment decision-makers. Both hold PhDs in molecular biology and do not delegate portfolio construction to a committee or outside analysts. The firm has no chief investment officer separate from the brothers.

Baker Brothers was the largest shareholder of Seagen before Pfizer's $43B acquisition closed in September 2023. The firm had held a substantial position for over two decades, with its ownership stake exceeding 25% at times. The acquisition represented one of the largest exits in biotechnology history and a defining outcome for the firm's long-duration strategy.

The firm invests across the full life cycle of biotechnology companies, from early clinical-stage developers with sub-$1B market capitalizations to large-cap commercial entities. Holdings have included micro-cap pre-revenue companies and mature global pharmaceutical platforms like BeiGene, reflecting a willingness to hold positions through any stage of development.

The Baker Brothers Foundation is the philanthropic vehicle of Julian and Felix Baker, funded by their investment activities. It focuses on biomedical research grants, particularly in immunology and cancer, as well as Jewish community organizations. The foundation operates as a separate legal entity from the investment adviser.